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- Development of liposome using the guarana powder, an essential Amazonian species. 
- The presence of polysorbate 80 induces a hemolytic process in the liposome. 
- The addition of guarana to liposome helps to protect erythrocytes. 
- Guarana-loaded liposome keeps the potent antioxidant activity of guarana. 
 
Abstract: Paullinia cupana var. sorbilis (Mart.) Ducke, popularly known as guarana, is one of the most 
promising plants in Brazilian flora and has attracted considerable interest from the scientific community owing 
to its numerous therapeutic activities and less side effects. Hence, using nanotechnology is a viable alternative 
to primarily improve the physicochemical characteristics and bioavailability of guarana. The objective of the 
present study was to develop, characterize, and evaluate the stability of liposomes containing guarana powder 
and to evaluate their antioxidant and hemolytic activity in vitro. Three different concentrations of guarana 
powder and two methods of liposome preparation were tested. Liposomes were developed and characterized, 
and their stability was analyzed by evaluating physicochemical parameters. Hemolytic activity of guarana 
liposomal formulation (G-Lip) was compared with that of guarana in its free form (FG) and of liposome 
without guarana (W-Lip). Red blood cells from rats were exposed to these different formulations dissolved in 
phosphate buffer solution (PBS; pH 7.4). The best stability was achieved for the formulation containing 1 
mg.mL−1 guarana powder produced by the reverse phase evaporation method. FG showed dose-dependent 
antioxidant activity, which was maintained in G-Lip. W-Lip showed high hemolytic activity in PBS at pH 7.4 
possibly because of the presence of polysorbate 80, and on addition of guarana to these structures, the 










complex structure of guarana, primarily the presence of polyphenols, exerts a powerful antioxidant action, 
helping to protect erythrocytes. 
Keywords: nanoparticle; Paullinia cupana; methylxanthines; polyphenols. 
1. Introduction 
Brazil houses the world’s greatest biodiversity, containing more than 41,000 species of plants [1]. The 
Amazon region itself contains at least 10,000 species of plants containing active components for medicinal use 
[2]. Among these, we focused on guarana [Paullinia cupana var. sorbilis (Mart.) Ducke], an Amazonian 
species, which has been historically cultivated and has multiple uses [3]. Currently, guarana is also used 
worldwide for the production of caffeinated energy drinks [4]. 
The vast chemical composition of guarana guarantees its biological activity potentiality. The main 
compound is caffeine (CAF; 3.2%–7%), which can exceed up to three times the amount found in coffee [5]. 
Moreover, other methylxanthines, such as theobromine (TEOB) and theophylline (TEOF), as well as 
polyphenols, catechin (CAT) and epicatechin (EPICAT), have been reported as major active compounds of 
guarana [6-8]. Guarana chemical matrix found in roasted seeds has been reported to exert several biological 
properties, such as antioxidant [9-11], antimicrobial [12], hypocholesterolemiant [13], anti-inflammatory, 
immunomodulatory [14], genoprotective [15], and hepatoprotective [16] activities. Furthermore, guarana also 
modulates triglyceride levels in overweight individuals [17-18] by modulation of the purinergic system [19] 
and is used to reverse inflammatory alterations programmed by maternal obesity in adult mice [20]. 
Guarana also has important actions on cognition and memory [21-23], which seem to involve modulation 
of acetylcholinesterase activity [19, 24], suggesting the therapeutic use of guarana supplements. Furthermore, 
it also exhibits synergistic activity with chemotherapeutic drugs for the treatment of colorectal and breast cancer 
[25-27] and exhibits a hermetic effect on bladder cancer cells (T24) by reducing cell viability and proliferation 
[28]. Prior studies, such as that performed by Palma et al. [29], have also suggested that guarana intake could 
improve chemotherapy-related fatigue in women with breast cancer. 
As for most products from plant extracts, one of the main problems of guarana is its physicochemical 
instability and vulnerability to possible degradation processes, which, in turn, may lead to a decrease in 
beneficial effects [30]. Furthermore, some bioactive molecules present in guarana matrix, such as polyphenols, 
could have low solubility and bioavailability [31-32]. Therefore, to improve the biopharmaceutical and 
technological properties of plant extracts, some strategies have been proposed based on nanotechnology, such 
as liposomes, nanoemulsions, and nanocapsules [33]. Liposomes are biocompatible and biodegradable vesicles 
formed essentially by phospholipids; they are amphiphilic molecules containing polar heads and hydrophobic 
hydrocarbon tails that have the ability to self-associate spontaneously and form bilayer vesicles dispersed in 
water, allowing the incorporation of hydrophilic and hydrophobic substances [34-35]. 
In this sense, the development of a safe nanotechnological product that contributes to the preservation 
of active compounds present in guarana is fundamental. Moreover, understanding its physicochemical 
characteristics, stability, and toxicity evaluation are essential steps to guarantee its safety and effectiveness [36]. 
Evaluation of hemolytic activity, using red cells as alternative tools, can be considered as a predictive 
cytotoxicity assay for different compounds to determine possible damage to the erythrocyte membrane [37-38]. 
These cells are devoid of internal membrane structures, are easy to isolate and handle, and have structures that 
are vulnerable to peroxidation, making them good biological membrane models for analyzing oxidative stress 
and lipid peroxidation of various compounds. Alterations in these cells may indicate the formation of reactive 
oxygen species, which cause oxidative damage in tissues [39].  
Considering the potential therapeutic use of guarana, the present study was conducted with the aim to 
develop and characterize a liposomal system containing guarana powder with the purposes of improving its 
stability and guaranteeing its pharmacological activities in addition to evaluating the effect on red blood cell 
membrane by hemolytic analysis. 
2. Materials and Methods 
2.1 Materials 
Analytical-grade acetonitrile, cholesterol, 2,2-diphenyl-1-picrilhydrazyl (DPPH), and polysorbate 80 










acquired from J.T.Baker® (Mexico City, Mexico). Ethanol was acquired from Synth® (São Paulo, Brazil). 
Monobasic potassium phosphate was acquired from F Maia® (São Paulo, Brazil). Sodium chloride and dibasic 
sodium phosphate were obtained from Nuclear® (São Paulo, Brazil). Potassium chloride was obtained from 
Qhemis® (São Paulo, Brazil). Lipoid S100® was from Lipoid® (Ludwigshafen, Germany), and vitamin E was 
from Alpha Química® (Porto Alegre, Brazil). Guarana powder was kindly provided by Agropecuary Research 
Brazilian Enterprise (EMBRAPA Western Amazon - Manaus, Amazon, Brazil). 
2.2. Pre-formulation study 
Initially, formulations were prepared with different concentrations of guarana powder (10.0 mg.mL−1, 
5.0 mg.mL−1, and 1.0 mg.mL−1) using different methods of producing liposomes, viz., ethanol injection (EI) 
and reverse phase evaporation (RP) methods. Liposomes were produced and stored at room temperature (RT) 
and under refrigeration (RE), and their particle size and polydispersion index (PDI) were evaluated at different 
times. 
The objective of the pre-formulation study was to evaluate the behavior of guarana at different 
concentrations when associated with liposomes produced by different methods to choose the formulation for 
further experiments. 
2.3 Preparation of guarana-loaded liposomes 
Liposomes containing guarana powder (G-Lip) were prepared by RP [40-41] and EI [42] methods. In 
the RP method, phospholipid, cholesterol, and vitamin E were solubilized in ethanol with the aid of ultrasound. 
Next, an aliquot of guarana powder and polysorbate 80 in phosphate buffer (pH 7.4) in the aqueous phase was 
mixed with this solution and sonicated again to produce a dispersion of reverse micelles. Subsequently, the 
organic solvent was removed by evaporation to form an organogel; this organogel was reverted into vesicles 
following the addition of the aqueous phase remainder under stirring (300 rpm) for 30 min using a rotary 
evaporator in a 40 °C water bath. In the EI method, the same constituents and quantities were used; however, 
in this method, the lipid and aqueous phases were solubilized separately, and after complete solubilization, the 
lipid phase was poured over the aqueous phase. The system was maintained on shaking for 10 min to form 
liposome dispersions. Subsequently, the organic solvent was evaporated using a rotary evaporator (300 rpm) in 
a 40 °C water bath. 
For both methods, the vesicles were homogenized by sequential filtration using cellulose acetate filter 
membranes of 0.45 and 0.22 μm porosity (Millex®, USA). For the most appropriate concentration and 
production method, white liposomes (W-Lip) were prepared without guarana powder as mentioned above. All 
formulations were prepared in duplicates. 
2.4 Physicochemical characterization of liposomes and evaluation of stability  
2.4.1 Particle size and zeta potential analysis 
Liposomes were analyzed for particle size by two different techniques, viz., laser diffraction (Microtrac 
S3500®, EUA) and dynamic light scattering (Zetaziser Nano-ZS®, Malverm, United Kingdom) using samples 
diluted in ultra-pure water (1:500 v/v). Moreover, dynamic light scattering was performed to determine the PDI. 
Zeta potential values of the liposomes were evaluated by the determination of electrophoretic mobility 
(Zetaziser Nano-ZS®, Malverm, United Kingdom). Measurements were performed after dilution of the 
formulations in 10 mM NaCl aqueous solution. 
2.4.2 Determination of pH 
The pH values of formulations were determined directly from dispersions using a previously calibrated 
potentiometer (Digimed DM22®, Brazil). 
2.4.3 Determination of the main active compounds and encapsulation efficiency (EE%) 
Quantification of main active compounds present in guarana powder (TEOB, TEOF, CAF, CAT, and 
EPICAT) and EE% estimation was done by reversed-phase high-performance liquid chromatography (RP-
HPLC) using Prominence chromatograph (Shimadzu®, Japan) equipped with a pump (model LC-20AT), photo 










mm) (Phenomenex®, Torrance, USA) and pre-column (4 × 3 mm, 5 mm) (Phenomenex®, Torrance, USA). The 
mobile phase consisted of water acidified with 0.1% TFA (phase A) and methanol:acetonitrile (25:75; v/v; 
phase B) in a ratio of 90:10 (v/v) of phase A:B followed by isocratic elution. The oven temperature was 30 °C, 
mobile phase flow of 1 mL.min−1, and injection volume of 20 μL. Active compounds were detected at 280 nm. 
The five major compounds in guarana powder sample were determined by quantifying the compounds 
from a guarana solution at a final concentration of 500 Pg.mL−1 prepared by solubilization in a solution of 
deionized water and methanol (1:1, v/v). For liposomes containing 1 mg.mL−1 guarana powder, samples were 
also prepared at the concentration of 500 Pg.mL−1 using a solution of methanol and mobile phase (1:1, v/v) as 
the solvent. 
EE% was determined by ultrafiltration–centrifugation technique (Microcon®- Millipore 10,000 Å) 
according to the methodology adapted from Ourique et al. [43]. The ultrafiltrate was obtained by centrifugation 
of 500 PL of guarana liposome samples for 10 min at 500 rpm. 
2.4.4 Stability studies 
After selecting guarana powder concentrations with better characteristics and stability, liposomes were 
produced again (in duplicates) and characterized according to the parameters described previously in section 
2.4 (2.4.1–2.4.3). Stability was evaluated over a period of 30 days for the samples produced in duplicates and 
stored under RE at 5 qC ± 2 qC. 
2.4.5 Morphology 
Based on physicochemical characterization and stability study, the best formulation was selected and 
liposomes were evaluated for their size and morphology by cryo-transmission electron microscopy (Cryo-TEM) 
using Tecnai F20 200kv FEG® (Thermo Fisher Scientific, Eindhoven, The Netherlands). Analyses were 
performed at the Scientific and Technological Center of the University of Barcelona, Spain. 
Briefly, 3 μL of G-Lip and W-Lip liposomes were placed on a Lacey carbon film in 200-mesh copper 
grids. Films were vitrified by ethane immersion and maintained at their melting point with liquid nitrogen using 
Vitrobot Mark III® (Thermo Fisher Scientific - Eindhoven, The Netherlands) by holding the sample at 100% 
moisture before freezing. Samples were analyzed at a temperature between −170 °C and −175 °C and recorded 
at 200 kV with an Eagle CCD camera of 4096 × 4096 pixels (FEI Company, Eindhoven, Netherlands). 
 
2.5 Antioxidant activity 
 
The liposomal antioxidant activity of G-Lip, W-Lip, and FG was evaluated by the DPPH method. This 
assay is based on the ability of an antioxidant substance to sequester the free radical DPPH and reduce it to 2,2-
diphenyl-1-picrilhydrazyl with accompanying color change from violet to pale yellow according to the method 
described by Choi et al. [44]. 
Treatments were prepared at final concentrations of 1, 10, 25, and 50 µg.mL−1 using ethyl alcohol as the 
solvent and incubated under light protection for 30 min. Treatments were evaluated in relation to a control 
sample (white control) without DPPH and a negative control sample (only DPPH in solvent). The absorbances 
of the samples were determined using a UV/VIS spectrophotometer (UV-1650 PC; Shimadzu®, Kyoto, Japan) 
at a wavelength of 517 nm using absolute ethyl alcohol as the blank. The assay was performed in triplicate. The 
calculation of the ability to sequester DPPH molecule free radicals was determined by the following equation: 
% inhibition = 100 − [(sample absorbance − blank absorbance) × 100]/control absorbance. 
2.6 Hemolysis assay  
The hemolytic activity of G-Lip, W-Lip, and FG was evaluated by hemolysis assay using erythrocytes 
as a model for general cytotoxicity evaluation. For this purpose, rat erythrocytes were isolated from blood 
collected in EDTA tubes. The procedure was approved by the ethical committee of animal experimentation of 
University of Barcelona (UB), Spain. Red blood cells were isolated by centrifugation at 3000 rpm for 10 min 
and washed three times with an isotonic phosphate buffer solution (PBS; pH 7.4) [38]. 
In order to avoid false negative results, the ability of liposomes to capture hemoglobin was evaluated 
prior to assays. The objective of this procedure was to verify the interaction of liposomes with hemoglobin. The 










shaking and hemoglobin release, 500 μL of liposome formulation was added. This solution was kept under 
stirring for 1 h, followed by centrifugation at 10,000 rpm for 5 min (Heraeus Biofuge Pico®, Germany). The 
ability of the liposomes to capture hemoglobin was then observed. 
For the hemolysis assay, 25-μL aliquots of erythrocytes were exposed to 500 μg.mL−1 FG, G-Lip, or W-
Lip dissolved in PBS solution (pH 7.4) at a final volume of 1 mL [38]. Controls were prepared by resuspending 
erythrocyte suspension either in buffer alone (negative control) or in distilled water (positive control). Cells 
were maintained in different treatments for 1 and 24 h under agitation, followed by centrifugation at 10,000 
rpm for 5 min. Supernatants were collected, and the hemoglobin released was detected by absorbance measured 
at 540 nm using a double-beam Shimadzu UV-VIS 160A® spectrophotometer (Kyoto, Japan). Percentages of 
hemolysis were determined by comparison with positive control samples totally hemolyzed with distilled water. 
The same experimental protocol was performed for each component present in the formulation of 
liposomes (cholesterol, phospholipid, vitamin E, and polysorbate 80). Tests were performed considering 
concentrations of each component in the formulation, and PBS (pH 7.4) was used for solubilization. For 
lipophilic compounds, 1% ethanol was added to facilitate their solubilization. 
2.7 Statistical analysis 
All experiments were performed in triplicates. Results are expressed as mean ± standard deviation (SD). 
One-way analysis of variance (ANOVA) was used to determine statistical differences between data sets, 
followed by Dunnett’s or Tukey’s post-hoc test for multiple comparisons. All statistical analyses were 
performed using GraphPad Prism 7.0 software® (GraphPad Software, Inc., CA, USA). p < 0.05 value was 




3.1 Pre-formulation study 
Formulations containing 10.0 mg.mL−1 of guarana powder had initial mean particle diameter of 
approximately 164 nm and 169 nm when produced by the RP and EI methods, respectively. The formulations 
remained stable for 14 days, after which an increase in mean particle diameter and PDI were observed, primarily 
when stored at RT (Table 1). Subsequently, organoleptic characteristics of appearance, color, and odor were 
also altered (Figure 1: I-1B, I-1C, II-1B, and II-1C). 
Formulations with 5.0 mg.mL−1 of guarana powder maintained their characteristics for a period of 42 
days, after which changes were observed, primarily related to mean diameter and PDI, specifically in 
formulations produced by evaporation method in RP and stored at RT. Of the organoleptic characteristics 
studied, only color was altered in this period for samples stored at RT and produced by the EI method (Figure 
1: I-2B, I-2C, II-2B, and II-2C). 
Better stability was obtained for formulations containing 1 mg.mL−1 of guarana powder. They remained 
stable without change in the mean particle diameter, PDI, and organoleptic characteristics when stored under 
RE for 70 days for both production methods. However, when produced by the RP method and stored at RT, 
analysis at 70 days showed a mean micron diameter (1534 nm r 65.37), increase in PDI (0.493 r 0.09), and 
change in coloration (Table 1 and Figure 1: I-3B, II-3B, and II-3C). 
 
 
3.2 Physicochemical characterization and stability study 
Based on pre-formulation results, subsequent experiments were performed using only G-Lip containing 1 
mg.mL−1 of guarana powder produced by the RP and EI methods. 
Initially, the mean diameter of particles was characterized using laser diffraction technique. The objective 
was to verify if all particles had dimensions of the nanoscale range. It was observed that all vesicles had 











RP method and 201 nm ± 0.02 for liposomes produced by the EI method, similar to the diameter noted by 
dynamic light scattering (Figure 2). From this initial analysis, other physicochemical characteristics were 
evaluated, and results obtained are described in Figure 2. 
The particle diameter value obtained by photon correlation spectroscopy during the experimental period 
was kept stable at approximately 174 nm with a low PDI of 0.2 when produced by RP. Likewise, by the EI 
method, particles with diameter of 115–124 nm were obtained with a low PDI of approximately 0.1, which was 
stable for 30 days (Figure 2A and 2B). 
The initial zeta potential values of −8.50 mV ± 1.15 (RP) and −7.17 mV ± 0.28 (EI) were maintained 
without significant change (p > 0.05) during the 30 days of analysis (Figure 2C). 
As shown in Figure 2D, initial pH values were approximately 7.32 ± 0.01 and 7.62 ± 0.09 when 
liposomes were produced by the RP method and the EI method, respectively. By RP, these values were 
significantly altered (p < 0.05) to 6.61 ± 0.20 during 30 days of analysis. However, by the EI method, the values 











It is important to mention that liposomes were produced with guarana powder. For this, firstly, the 
concentration of the major compounds (TEOB, TEOF, CAF, CAT, and EPICAT) present in guarana powder 
was evaluated. Results showed the concentration of 20.61 Pg.mL−1 methylxanthines [0.14 Pg.mL−1 (0.028%) 
of TEOB, 0.47 Pg.mL−1 (0.094%) of TEOF, and 20.00 Pg.mL−1 (4.0%) of CAF] and 26.00 Pg.mL−1 of 
polyphenols [13.00 Pg.mL−1 (2.6%) of CAT and 13.00 Pg.mL−1 (2.6%) of EPICAT]. After production of 

















Both preparation methods (RP and EI) presented reductions in the content of active compounds, except 
for CAF, which remained stable (p > 0.05) for 30 days when stored RE (5 qC ± 2 qC) (Figure 3). 
When liposomes were prepared by RP, the content of TEOF (30 days), CAT (30 days), and EPICAT (15 
days) decreased. For CAF and TEOB, no reduction was observed during experiments. 
When liposomes were prepared by the EI method, TEOB (30 days), TEOF (7 days), CAT (7 days), and 
EPICAT (7 days) decreased significantly (p < 0.05). 
Among the compounds, EPICAT was the active substance that showed the highest concentration 
reduction. In 30 days of analysis, reductions of 43.76% were observed when liposomes were produced by the 











In parallel to quantification of active compounds, EE% of these compounds was determined. It was not 
possible to determine EE% for TEOB and TEOF by the employed method because their concentration in 
guarana is very low, making it difficult to determine the nanoencapsulated content of these compounds. For 
other active substances (CAF, CAT, and EPICAT) different EE% were observed regardless of the liposome 
production method. 
Interaction between drug and lipid vesicles decisively influenced its encapsulation in liposomes. Thus, 
higher encapsulation efficiencies for CAT [63.49 ± 1.90% (RP) and 47.80 ± 7.33% (EI)] and EPICAT [74.95 
± 5.08% (RP) and 71.36 ± 4.24% (EI)] were due to the higher lipophilic character of these substances, resulting 
in a greater interaction with the lipid lamellae and, consequently, higher EE% [45]. However, CAF presented 
EE% of 19.19 ± 4.53% when produced by the RP method and 2.35 ± 1.15% when produced by the EI method. 
These results were already expected due to the methods used to produce the liposomes. 
Although the formulation produced by the EI method presented some physicochemical characteristics, 
such as a smaller particle diameter, narrower PDI, and stable pH during the stability period, which were more 
suitable, the RP method was chosen as the most convenient method of producing liposomes containing 1 
mg.mL−1 of guarana powder. This choice was based primarily on the quantification and stability of active 
compounds and EE% of these compounds, primarily CAF. 
From this, remaining experiments were conducted only with liposomes containing 1 mg.mL−1 guarana 
powder produced by the RP method. 
It is also worth mentioning that by the RP method, W-Lip were also produced and characterized. These 
formulations had the following physicochemical characteristics: particle diameter of 172 nm ± 0.02 (laser 
diffraction) and 165 nm ± 2.39 (dynamic light scattering), PDI of 0.27 ± 0.02, zeta potential of −9.16 ± 0.57 
mV, and pH of 7.33 ± 0.02. It should be noted that presence of guarana did not alter the physicochemical 
characteristics of liposomes, maintaining their desirable characteristics. 
Similarly, photomicrographs obtained from Cryo-TEM for W-Lip and G-Lip evidenced the presence of 
spherical particles with an average diameter around 200 nm (Figure 4), indicating low polydispersity of the 
system. These results corroborated with the medium and low dispersion diameters obtained by laser diffraction 
and dynamic light scattering techniques, respectively, as shown in Figure 2. 
Formation of multilamellar (MLV) and unilamellar (LUV) liposomes systems was also observed, 
with a higher amount of unilamellar systems, as indicated in Figure 4. 
3.3 Antioxidant activity 
Antioxidant activity of guarana and liposomes (W-Lip and G-Lip) are shown in Figure 5. 
Regardless of the concentration tested, W-Lip showed no ability to sequester free radicals from the 
DPPH molecule. However, when DPPH was added to G-Lip and FG, antioxidant activity was observed at 
concentrations of 10, 25, and 50 µg.mL−1 of guarana. The free radical reduction for G-Lip was 10.90%, 27.76%, 
and 29.84% at concentrations of 10, 25, and 50 µg.mL−1, respectively. Similarly, for FG, 10.05%, 28.04%, and 
44.13% reductions of DPPH radicals were observed at concentrations of 10, 25, and 50 µg.mL−1, respectively. 
3.4 Hemolysis 
The hemolytic activity of guarana and liposomes (W-Lip and G-Lip) was determined after 1 and 24 h of 
incubation at a concentration of 500 Pg.mL−1 (Figure 6). 
The results obtained evidenced the non-hemolytic effects after 1 h of incubation for the different 
treatments (FG, W-Lip, and G-Lip). However, after 24 h of incubation, hemolysis was observed for W-Lip 
(hemolysis 100%). These results clearly showed that membrane lysis is caused by the liposomal structure (W-
Lip) after 24 h of exposure and indicates the protective effect of guarana. 
Hemolytic activity of constituents used in liposome preparation showed that polysorbate 80 (Tween 80®) 
was the only hemolytic component with values of approximately 33% and 100% after 1 and 24 h, respectively. 
Moreover, a low hemolytic process (around 7%) was observed for vitamin E after 1 h of contact with 












In this study, we incorporated guarana powder into liposomal dispersions, which presented adequate 
physicochemical and stability characteristics. Moreover, these liposomal dispersions did not cause hemolysis 
in contact with erythrocytes, indicating promising application in pharmaceutical, food, and cosmetic industries. 
From among different nanostructured systems, liposomes were selected for their biocompatibility, 
biodegradability [46], and primarily versatility in encapsulating amphiphilic compounds [47] like guarana. Soya 
phosphatidylcholine was the phospholipid of choice in our study as the use of natural phospholipids for 
liposome preparation generally presents a lower cost when compared with formulations prepared with synthetic 
phospholipids. These natural compounds generally exhibit high stability and biocompatibility, allowing 
production of lipid vesicles that are more resistant to oxidation processes [48]. Cholesterol was added to this 
phospholipid to improve the resistance of lipid membranes, thus increasing hydrophilic substance retention by 
reducing the rotational freedom of phospholipid hydrocarbon chains and inducing the formation of a less 
permeable structure [49]. Vitamin E, which acts as an antioxidant agent that prevents the oxidation of these 
substances and improves stability of liposomal dispersion, was also added [42,48]. 
Among various methods of liposome preparation, RP and EI methods were selected considering the 
laboratory conditions and possible industrial-scale production of these liposomes. The RP method afforded a 
higher rate of encapsulation of hydrophilic compounds, whereas the EI method was easy to perform [40,42,48]. 
To the best of our knowledge, considering this was the first time that guarana powder was associated 
with liposomes, pre-formulation studies were extremely important to select the ideal powder concentration to 
maintain the stability of the system. Through this initial study, the concentration of 1 mg.mL−1 of guarana 
powder showed better physicochemical characteristics, such as mean particle diameter, PDI, and organoleptic 
characteristics. 
PDI was used to determine homogeneity in particle size distribution in the dispersions. PDI values of 
≤0.3 are considered monodisperse systems [50]. In our study, when prepared by the EI method, PDI was 
significantly lower (p < 0.05) than that in the RP method (Figure 2B). As already described in literature, these 
results were already expected as the EI method allows obtaining small unilamellar liposomal vesicles associated 
with relatively narrow vesicle distribution [51], whereas liposomes produced by the RP method predominantly 
produces large unilamellar liposomes [40,42,51]. In this sense, data obtained in this research are in agreement 
with those reported in literature for liposomes produced by RP and EI methods [41-43]. 
The slightly negative zeta potential obtained in our results was already expected (Figure 2C), which is 
justified by the presence of phosphoric acid in phospholipids, such as phosphatidylcholine, used in this 
experiment [52]. Negative potential (−6.8 to −7.7 mV) for liposomes produced by the supercritical fluid method 
using Lipoid S100® and cholesterol has been also observed by Karn et al. [53]. 
Results of zeta potential are generally used to predict the stability of colloidal systems in general; the 
higher the zeta potential in module, the greater is the stability of these systems as particles tend to repel each 
other, thus avoiding aggregation and loss of stability [54-55]. The not-so-high zeta potential obtained in our 
study can be justified by steric stabilization. In this case, stabilization occurred by changing the shear plane to 
a much greater distance from the surface of the particles, which led to a reduction in the measured zeta potential. 
This shear change is often related to the absorbent layers of polymers and/or molecules [56]. 
The pH values were found to be around 7.4, as expected (Figure 2D), as PBS with pH 7.4 was used for 
liposome production. 
Stability analysis results (Figure 3) showed reductions in active compound content, particularly for 
catechins (CAT and EPICAT). This can be justified by the chemical structure of these compounds, which have 
an acid character, allowing degradation in neutral and/or basic medium. Data from literature show that neutral 
and basic conditions facilitate catechin degradation process, insofar under these conditions, catechins can 
undergo degradation as well as oxidation and polymerization [57-59]. Feng [60] reported that catechins present 
in green tea are generally unstable under neutral and alkaline conditions. 
In general, when liposomes were prepared by the RP method, the content of the active substances was 
maintained for a longer time than when prepared by the EI method. By the EI method, significant reductions (p 
< 0.05) in TEOF, CAT, and EPICAT content were observed in 7 days of stability. However, by the RP method, 
stability of these compounds was maintained for up to 15 days (EPICAT) and 30 days (TEOF and CAT) (Figure 
3). 
Data from literature show that the behavior and stability of liposomal vesicles can be controlled by the 










fluorouracil liposomes prepared by the RP method when compared with dry lipid film hydration methods, 
followed by extrusion and the EI method. 
CAT and EPICAT presented higher EE% when compared with CAF. These results are justified by higher 
lipophilicity of these compounds when compared with CAF. In general, lipophilic active compounds are 
incorporated into lipid bilayers, allowing greater incorporation and consequently higher EE% when compared 
with hydrophilic compounds that are generally dispersed in the aqueous phase [62]. Thus, low EE% values 
found for CAF [19.19 ± 4.53 % (RP) and 2.35 ± 1.15 % (EI)] were already expected as this compound presents 
higher hydrophilicity, consequently presenting a lower EE% when produced from soybean phosphatidylcholine 
[48,63]. 
In addition, as already described in literature and evidenced in our study when compared with other 
methods of liposome production, the RP method showed higher rates of encapsulation were obtained for 
hydrophilic compounds [36,54]. 
The antioxidant activity of guarana (Figure 5) was observed from the concentration of 10 µg.mL−1 and 
was maintained when this active substance was associated with liposomes. A dose-dependent activity was also 
evidenced for both FG and G-Lip. 
Numerous studies have already described the potential antioxidant effect of guarana [7,10,12-13,64-65]. 
Phenolic compounds, primarily found in guarana seeds, guarantees this activity. Similarly, their oxidation 
properties allow these compounds to act as a reducing agent by donating hydrogen and electrons. Another 
contributing factor is the chemical structure formed by at least one aromatic ring, which is attached to one or 
more hydroxyls, thus, playing an important role in neutralizing or sequestering free radicals and chelating 
transition metals, allowing to act in the initiation and propagation steps of the oxidative process [66]. 
Erythrocyte membrane resistance has been used by many authors as a tool in the evaluation of toxicity 
[67-72]. The hemolytic assay is based on the measurement of hemoglobin release from suspended red blood 
cells in solutions with gradual reduction in its concentrations in addition to detection of cells showing osmotic 
lysis. The released hemoglobin is positively correlated to the percentage of lysed cells [39]. 
Previously, for evaluating the hemolytic activity of guarana and liposomes, hemoglobin uptake by this 
liposomal system was studied. The results showed no interaction of liposomes with hemoglobin; therefore, the 
hemolysis experiments were conducted safely.  
The results of hemolytic evaluation clearly showed that cellular damage was caused by liposomal 
structure (W-Lip) in contact with blood cells for 24 h, but this was prevented by the presence of guarana, which 
is an important anti-hemolytic compound (Figure 6). 
The hemolytic effect observed for W-Lip can be attributed to a possible cytotoxic effect caused by 
polysorbate 80, which has previously been reported in literature. Tatsuishi et al. [73] observed that polysorbate 
80 has the ability to increase cytotoxicity of hydrogen peroxide in vitro, thus, increasing cellular susceptibility 
to oxidative stress. 
In addition, protection against cellular damage observed for G-Lip (Figure 6) can be justified by the 
potent antioxidant capacity found in our study (Figure 5) and also described in literature for guarana [7,10,12-
13,64]. Flavonoids and polyphenols in erythrocyte membranes have a beneficial effect on membrane stability 
and protect the membrane from degradative processes like hemolysis [74-76]. It is believed that one of the 
factors contributing to membrane stabilization is related to Van der Waals excitation within the lipid bilayer by 
flavonoids [75]. 
In a study with aqueous extract of Thymus satureioides, a plant rich in polyphenols and flavonoids, 
Ranchoun et al. [77] observed that this extract neutralizes the free radicals released by 2,2-azobis-
amidinopropane (AAPH) radical and can revert hemolysis induced by this radical. Justification for this 
erythrocyte protection ability is linked to the high content of polyphenols and flavonoids present in this extract, 
which shows antioxidant activity by protecting the erythrocyte membrane from injury by avoiding and/or 
increasing the half-life of the hemolytic process. 
Baccarin et al. [78] suggested three possible mechanisms that lead to erythrocyte protection by products 
containing polyphenols. The first mechanism is related to partition coefficient or to the degree of lipophilicity 
of phenolic compounds that determines its interaction with biomembranes, which is a determining factor in its 
antioxidant capacity and/or ability to interact with free radicals. Second, the chemical structure of phenolic 
compounds determines their ability to react with free radicals. This ability is directly related to the number of 










continuation of oxidative process. Moreover, a third mechanism may be related to the synergism of different 
phenolic compounds that may contribute to oxidation inhibition. 
Likewise, Bouhlali et al. [79] evaluated the antioxidant and antihemolytic activity of six varieties of 
Phoenix dactylifera L., and, similar to previous studies, attributed the stabilization of erythrocyte membrane to 




Liposomes containing 1 mg.mL−1 of guarana powder were successfully produced by the RP method. These 
structures presented adequate nanometric and physicochemical characteristics with the type of system 
developed, enabling future applications as nanomedicine. Hemolytic evaluation showed that W-Lip induces 
membrane damage caused by the presence of the surfactant polysorbate 80. Results obtained in this study 
allowed us to conclude that the presence of guarana in liposomes (G-Lip) affords protection against hemolytic 
process, possibly due to its flavonoid and polyphenol composition, which exert a potent antioxidant activity. 
This formulation demonstrates as a potential nanomedicine to be explored further. In this sense, more tests are 
being performed to prove the efficiency and safety of guarana-containing liposomes. 
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Figure 1 – Organoleptic characteristics of formulations prepared by RP (I) and EI (II) methods. (1) 10.0 mg.mL−1; 
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Figure 2 – Physicochemical parameters of liposome formulations containing 1 mg.mL−1 guarana powder stored at 
RE (n = 2). A: Particle size (nm); B: PDI; C: Zeta potential (mV); and D: pH. RP, liposomes containing 1 mg.mL−1 
of guarana powder produced by the RP method; EI, liposomes containing 1 mg.mL−1 of guarana powder produced by 






























Figure 3 - Total content of active ingredients present in liposomes containing 1 mg.mL−1 guarana powder stored under 
RE (n = 2). A, liposomes produced by the RP method; B, liposomes produced by EI method. TEOB (theobromine), 
TEOF (theophylline), CAF (caffeine), CAT (catechin), and EPICAT (epicatechin) content. * Value presents 












Figure 4 – Photomicrographs obtained by Cryo-TEM from liposome dispersions. A, white liposomes (W-Lip); B, 





Figure 5 – Antioxidant activity for different treatments. FG (free guarana), W-Lip (white liposomes), G-Lip 
(liposomes containing guarana). *Statistically significant difference (p < 0.05) when compared with positive control 






































































Figure 6 – Hemolytic activity for different treatments. FG (free guarana at 500 Pg.mL−1 concentration), W-Lip (white 
liposomes), G-Lip (liposomes at 500 Pg.mL−1 concentration). *Statistically significant difference (p < 0.05) when 




















PDI r DP 
Particle 
diameter (nm) 
 r DP 








1 Initial 164 r 6.32 0.426 r 0.02 169 r 0.23 0.238 r 0.02 
RT -14 days 653 r 184.69 0.696 r 0.12 596 r 266.32 0.706 r 0.21 







1  Initial 140 r 8.42 0.343 r 0.05 115 r 1.53 0.168 r 0.01 
RT - 42 days 241 r 27.84 0.710 r 0.09 175 r 2.08 0.477 r 0.01 







1  Initial 163 r 8.63 0.313 r 0.01 132 r 0.57 0.181 r 0.01 
RT - 70 days 1534 r 65.37 0.493 r 0.09 155 r 2.76 0.242 r 0.01 
RE - 70 days 168 r 5.15 0.372 r 0.04 141 r 2.97 0.181 r 0.01 
RT (room temperature, 25 qC ± 2 qC), RE (under refrigeration, 5 qC ± 2 qC) 
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